{ "meta": { "data_length": 1, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A878", "status": "success", "status_code": 200, "timestamp_elapsed": 0.00414, "timestamp_received": "2026-09-25T00:13:53.784334+00:00Z", "timestamp_returned": "2026-09-25T00:13:53.788474+00:00Z", "trace_id": "817b4724-d309-403b-825e-d36f03bebc21" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:vanflyta:0:1", "type": "Statement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to quizartinib in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as a maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. This indication is based on QuANTUM-First (NCT02668653), a randomized, double-blind, placebo-controlled trial of 539 patients where patients received cytarabine with either daunorubicin or idarubicin.", "contributions": [ { "id": "ctrb:vanallenlab:2025-10-03:1", "type": "Contribution", "description": "On 2023-07-20 the FDA granted granted approval to quizartinib in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as a maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.", "date": "2025-10-03", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2023-07-20:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2023-07-20", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:vanflyta", "type": "Document", "documentType": "Regulatory approval", "name": "Vanflyta (quizartinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Daiichi Sankyo, Inc. Itovebi (inavolisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216993s001lbl.pdf. Revised June 2024. Accessed October 3, 2025.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216993s001lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216993" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Daiichi Sankyo, Inc.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Vanflyta", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "quizartinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2023-07-20", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 216993, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-06-25", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:878", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:oncotree:AML", "conceptType": "Disease", "name": "Acute Myeloid Leukemia", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": false, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:oncotree:AML", "code": "AML", "name": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML" ] } }, "objectTherapeutic": { "id": "txgrp:192", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C408", "conceptType": "Therapy", "name": "Cytarabine", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:3041", "code": "3041", "name": "cytarabine", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=3041" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1311078", "code": "1311078", "name": "cytarabine", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1311078" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:387511003", "code": "387511003", "name": "Cytarabine", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=387511003&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4306038", "code": "4306038", "name": "Cytarabine", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4306038" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "DNA Polymerase inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C408", "code": "C408", "name": "Cytarabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408" ] } }, { "id": "tx:ncit:C62091", "conceptType": "Therapy", "name": "Daunorubicin", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:3109", "code": "3109", "name": "daunorubicin", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=3109" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1311799", "code": "1311799", "name": "daunorubicin", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1311799" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:372715008", "code": "372715008", "name": "Daunorubicin", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=372715008&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4156866", "code": "4156866", "name": "Daunorubicin", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4156866" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Topoisomerase inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C62091", "code": "C62091", "name": "Daunorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091" ] } }, { "id": "tx:ncit:C68936", "conceptType": "Therapy", "name": "Quizartinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2643048", "code": "2643048", "name": "quizartinib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2643048" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:746225", "code": "746225", "name": "quizartinib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/746225" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "FLT3 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C68936", "code": "C68936", "name": "Quizartinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68936" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:66", "present": true, "subject": { "id": "bmkr:66", "type": "CategoricalVariant", "name": "FLT3-ITD", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.53HN2VFdgurjdPcQYBRwyfNMHcwRzdID", "type": "SequenceLocation", "name": "FLT3 ITD Region (Exons 14-15), protein", "aliases": [], "description": "Sequence within refseq:NP_004110.2, the protein product of the MANE Select coding transcript for FLT3 (refseq:NM_004119.3), corresponding to the juxtamembrane domain and N-terminal portion of tyrosine kinase subdomain 1 (Exons 14-15).", "digest": "53HN2VFdgurjdPcQYBRwyfNMHcwRzdID", "sequenceReference": { "id": "ga4gh:SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH", "type": "SequenceReference", "name": "NP_004110.2", "aliases": [ "ensembl:ENSP00000241453.7", "ga4gh:SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH", "refseq:NP_004110.2" ], "description": "The protein product of the MANE Select coding transcript for FLT3 (refseq:NM_004119.3), corresponding to the Refseq protein accession NP_004110.2.", "moleculeType": "protein", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH", "residueAlphabet": "aa" }, "start": 568, "end": 648, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:3765", "conceptType": "Gene", "name": "FLT3", "primaryCoding": { "id": "coding:hgnc:3765", "code": "HGNC:3765", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000122025", "code": "ENSG00000122025", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000122025" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:2322", "code": "2322", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/2322" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004119.3", "code": "NM_004119.3", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "13" }, { "name": "start_position", "value": null }, { "name": "end_position", "value": null }, { "name": "reference_allele", "value": null }, { "name": "alternate_allele", "value": null }, { "name": "cdna_change", "value": null }, { "name": "protein_change", "value": null }, { "name": "variant_annotation", "value": "Internal Tandem Duplication (ITD)" }, { "name": "exon", "value": null }, { "name": "rsid", "value": null }, { "name": "hgvsg", "value": null }, { "name": "hgvsc", "value": null }, { "name": "requires_oncogenic", "value": true } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:vanflyta:0", "type": "Indication", "description": "VANFLYTA is a kinase inhibitor indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.", "contributions": [ { "id": "ctrb:vanallenlab:2025-10-03:1", "type": "Contribution", "description": "On 2023-07-20 the FDA granted granted approval to quizartinib in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as a maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.", "date": "2025-10-03", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2023-07-20:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2023-07-20", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:vanflyta", "type": "Document", "documentType": "Regulatory approval", "name": "Vanflyta (quizartinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Daiichi Sankyo, Inc. Itovebi (inavolisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216993s001lbl.pdf. Revised June 2024. Accessed October 3, 2025.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216993s001lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216993" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Daiichi Sankyo, Inc.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Vanflyta", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "quizartinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2023-07-20", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 216993, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-06-25", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }